Trial
NCT00130936
Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates
Phase ITERMINATEDSAFETYConfidence: HIGH
Sponsor
AHS Cancer Control Alberta
Collaborators
—
Condition
Gastric Cancer
Intervention
Epirubicin
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-02-15